Publication Name	World Journal of Hepatology
Manuscript ID	91355
Country	India

Received	2023-12-27 13:10
Peer-Review Started	2023-12-27 13:10
To Make the First Decision
Return for Revision	2024-01-13 16:42
Revised	2024-01-24 15:11
Second Decision	2024-03-04 02:52
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-03-04 06:32
Articles in Press	2024-03-04 06:32
Publication Fee Transferred
Edit the Manuscript by Language Editor	2024-03-01 12:48
Typeset the Manuscript	2024-03-13 03:29
Publish the Manuscript Online	2024-03-27 13:28

ISSN	1948-5182 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Hepatocellular carcinoma immune microenvironment and check point inhibitors-current status
Manuscript Source	Invited Manuscript
All Author List	Tarana Gupta and Nikhil Sai Jarpula
Funding Agency and Grant Number
Corresponding Author	Tarana Gupta, MBBS, MD, Professor, Researcher, Division of Hepatology, Department of Medicine, Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, House No. 1065A Sector 1, Rohtak 124001, Haryana, India. taranagupta@gmail.com
Key Words	Hepatocellular carcinoma; Tumour immune microenvironment; Immune checkpoint inhibitor; Atezolizumab; Bevacizumab; Pembrolizumab
Core Tip	Hepatocellular carcinoma (HCC) is a prototype of inflammation associated cancer. Its varied etiology from viral to alcohol and non-alcoholic steatohepatitis, tumor extent, intrahepatic spread, vascular invasion and metastases along with underlying severity of liver dysfunction make it a complex scenario for adequate management. The recent elaboration of tumor microenvironment revealing immunogenic milieu and bringing the concept of “Cold” and “Hot” tumor opened the way for evaluation of immunotherapy in HCC. In recent years, with use of immune checkpoint inhibitors, there is a paradigm shift in management of advanced and unresectable HCC. With use of combination regime including immune checkpoint inhibitors and trans arterial chemoembolization/ablation/tyrosine kinase inhibitors, there is an ongoing effort at improving disease outcomes and minimizing the adverse events.
Publish Date	2024-03-27 13:28
Citation	Gupta T, Jarpula NS. Hepatocellular carcinoma immune microenvironment and check point inhibitors-current status. World J Hepatol 2024; 16 (3): 353-365
URL	https://www.wjgnet.com/1948-5182/full/v16/i3/353.htm
DOI	https://dx.doi.org/10.4254/wjh.v16.i3.353

Full Article (PDF)	WJH-16-353-with-cover.pdf
Manuscript File	91355_Auto_Edited-JRF-Webster J-YJP.docx
Answering Reviewers	91355-Answering reviewers.pdf
Audio Core Tip	91355-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	91355-Conflict-of-interest statement.pdf
Copyright License Agreement	91355-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	91355-Language certificate.pdf
Peer-review Report	91355-Peer-review(s).pdf
Scientific Misconduct Check	91355-Bing-Fan JR-2.png
Scientific Editor Work List	91355-Scientific editor work list.pdf
CrossCheck Report	91355-CrossCheck report.pdf
CrossCheck Report	91355-CrossCheck.png